key: cord-1018614-fqtibjgh authors: Al-Abri, Seif Salem; Al-Wahaibi, Adel; Al-Kindi, Hanan; Kurup, Padmamohan J; Al-Maqbali, Ali; Al-Mayahi, Zayid; Al-Tobi, Mohammed Hamed; Al-Katheri, Salim Habbash; Albusaidi, Sultan; Al-Sukaiti, Mahmood Humaid; Al Balushi, Ahmed Yar Mohammed; Abdelgadir, Iyad Omer; Al-Shehi, Nawal; Morkos, Essam; Al-Maani, Amal; Al-Rawahi, Bader; Alyaquobi, Fatma; Alqayoudhi, Abdullah; Al-Harthy, Khalid; Al-Khalili, Sulien; Al-Rashdi, Azza; Al-Shukri, Intisar; Al Ghafri, Thamra S; Al-Hashmi, Fatma; Al Jassasi, Saeed Mussalam; Alshaqsi, Nasser; Mitra, Nilanjan; Al Aamry, Humaid Suhail; Shah, Parag; Al Marbouai, Hanan Hassan; Al Araimi, Amany Hamed; Kair, Ismail Mohammed; Al Manji, Asim Mohammed; Almallak, Ahmed Said; Al Alawi, Fatma Khamis; Vaidya, Vidyanand; Muqeetullah, Muhammad; alrashdi, Hanan; Al Jamoudi, Saud Said Nassir; Alshaqsi, Asila; Al Sharji, Abdullah; Al Shukeiri, Hamida; Al-Abri, Badr; Al-Rawahi, Sulaiman; Al-Lamki, Said H; Al-Manji, Abdulla; Al-Jardani, Amina title: SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys date: 2021-09-30 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.09.062 sha: 3252910082f11f32a2b28cc1943ebd0262c9d309 doc_id: 1018614 cord_uid: fqtibjgh Objective To assess SARS-COV-2 seroprevalence in Oman and longitudinal changes in antibody levels over time within the first 11 months of the COVID-19 pandemic. Methods This nationwide cross-sectional study was conducted as a four-cycle serosurvey using a multistage stratified sampling method from July–November 2020. A questionnaire was used and included demographics, history of acute respiratory infection and list of symptoms, COVID-19 contact, previous diagnosis or admission, travel history, and risk factors. Results In total, 17,457 participants were surveyed. Thirty percent were female, and 66.3% Omani. There was significant increase in seroprevalence throughout the study cycles, starting from [5.5 (4.8–6.2)] for the first cycle and ending with [22 (19.6–24.6)] for the forth cycle. There was no difference in seroprevalence between genders, but significant differences between age groups. There was a transition of seroprevalence from being higher in non-Omanis in cycle one, [9.1 (7.6–10.9)] to Omanis [3.2 (2.6–3.9)] to being higher in Omanis [24.3 (21.0–27.9)] to non-Omanis [16.8 (14.9–18.9)] in cycle four. There was remarkable variation in seroprevalence of COVID-19 according to governorate. Close contacts of people with COVID-19 had a 96% higher risk of having the disease, (adjusted odds ratio [AOR]=1.96, 95% confidence interval [CI] 1.64–2.34); laborers have 58% higher risk of infection compared to office workers (AOR=1.58, 95% CI; 1.04–2.35). Conclusion The study showed a wide variation of SARS-CoV-2 dissemination between governorates in Oman, with higher seroprevalence estimates in migrants in the first two cycles. Prevalence estimates remain low and are insufficient to provide herd immunity. Coronavirus 19 disease (COVID-19) is a severe, acute respiratory syndrome caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); it was first identified in Wuhan, China in December 2019 (Zhu et al., 2020; Huang et al., 2020) , and within months spread to most nations of the world (WHO, 2021; Hick and Biddinger, 2020) . The surveillance of confirmed COVID-19 cases may not represent a particular community, since the manifestation of SARS-CoV-2 infection ranges from asymptomatic to fatal (Xu et al, 2020; Stringhini et al., 2020) . Although reverse transcription polymerase chain reaction (RT-PCR) testing is currently recognized as the gold standard for the diagnosis of SARS-CoV-2 infection (Chan et al., 2020) , the true number of SARS-CoV-2 infections is much higher than the officially reported number of cases. This is due to several factors, including the occurrence of asymptomatic infections, variable seeking of health care for clinically mild cases, variation in testing strategies between and within countries, and incomplete case reporting (Chen et al., 2021; Rostami et al., 2021) . Therefore, the reported COVID-19 cases, based on clinical identification with virological confirmation, only represent a small proportion, and a large number of asymptomatic and mild infections in the general population might only be identified by seroepidemiological studies (Rostami et al., 2021; Munster et al., 2020) . 6 Serological studies are an important tool to evaluate the cumulative prevalence of SARS-CoV-2 infection in the general population (Xu et al., 2020; Rostami et al., 2021; Thomas et al., 2021) , estimate the proportion of the population previously infected, quantify the magnitude of the transmission of pathogens, estimate the infection fatality rate (Stringhini et al., 2020) , assess the effect of interventions (Sughayer et al., 2020) , and when correlates of protection are available, estimate the degree of population immunity (Chen et al., 2021; Griffin 2020; Verity et al., 2020) . It is expected that serological monitoring and surveillance, if undertaken routinely, can be valuable for policymakers and health authorities when making public health decisions (Chen et al., 2021) . Oman is a country of 4.6 million and has a heterogeneous population, with migrants constituting 41% of the population according to the National Center for Statistical Information, Oman (2021). The first case of COVID-19 in Oman was confirmed on 24 February 2020 when two citizens tested positive for COVID-19 after returning from Iran (Al-Rawahi et al., 2021) . The government of Oman established a national supreme committee for the COVID-19 response in mid-March 2020 to coordinate the national response to the pandemic using a whole-of-government approach. Oman responded to the COVID-19 pandemic by implementing multiple non-pharmaceutical interventions in phases to control the disease, such as restricting flights from infected countries, closing schools and commercial activities, and restricting mass gatherings. In addition, other public health interventions have been instated, such as increasing testing capacity, addressing migrants' needs under universal health coverage, contact tracing and quarantine, using of face masks, encouraging hand hygiene, and maintaining social distancing (Al . The overall quality of seroprevalence studies is low, the majority of studies use convenience samples and rely on small or non-random sampling of participants while only a few used national-scale and multistage or stratified random sampling to select study participants (Chen et al., 2021; Bellizzi et al., 2021) . This study aimed to assess SARS-CoV-2 seroprevalence in the general population in Oman and to assess the longitudinal changes in antibody levels over time within the first 11 months of the pandemic prior to the launch of the national vaccination campaign, and how the changes correlate with time, sex, age, districts, and nationalities, and to the disease prevalence in the community. This study was conducted as a series of four-cycle serosurvey nationwide cross-sectional studies. The target population was the entire sultanate of Oman; all governorates (regions) and all wilayats (districts) in each governorate. The survey was done in four cycles, and each cycle lasted from five to 10 working days. There was a two to four weeks gap between each cycle (not less than one incubation period and not exceeding two incubation periods). The variation between the duration of the cycles and the gaps was due to the presence of public holidays. Hence, cycle one started on 12 of July 2020, 8 cycle two began on 16 August 2020, cycle three started on 13 September 2020, and cycle four started on 08 November 2020. Sample sizes were calculated based on 95% CI and 5% margin of error samples using Epi Info version 7.2 (Epi Info tm Atlanta, GA). To calculate the sample size, Oman was divided administratively into 11 governorates, each one counted as a unique population. For its larger population, which is around one third of Oman's population, Muscat governorate was divided into two areas and considered as two administrative areas where sampling was conducted from each area separately. This study was conducted using a multistage stratified sampling method. With the help of the telecommunications regulatory authority and the National Centre for Statistics and Information, phone numbers of residents in each governorate were used as the sample frame for the study. This was particularly useful because people who were physically present in governorates were targeted, not only by the registered address rather targeting mobile phones connected to telecom towers in each area. Random samples were selected from each governorate and phone numbers were distributed to the focal points in the governorates. The phone number was used to represent the household. In the household, the family was listed, sorted by age in descending order and numbered. One member from the household was 9 selected randomly using a random number generator mobile phone application. The focal points in the governorates were responsible for calling the participants, randomly selecting the house member, preparing them for the study and directing them to the nearest primary health care center to undergo the survey. Supplementary Table 1 shows the samples for each governorate in each cycle. In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate. The questionnaire data included: patient demographics (sex, age, house address, work address, nationality, occupation), history of acute respiratory infection and list of symptoms, COVID contact, previous diagnosis or admission, history of travel, and risk factors such as diabetes mellitus and hypertension (see Supplementary Table 2 ). The questionnaire was collected electronically by the attending physician in the primary health care system through Tarassud Plus, a ministry of health electronic record system. After consenting, the participant was then directed for serology sample collection. Blood test for serology of COVID-19 10 Specimens were collected, with appropriate infection control precautions, aseptically by venipuncture and the serum or plasma separated from clot, red cells, or gel separator, after centrifugation. Samples were then transported to central public health laboratories as soon as possible; if transportation was delayed, then samples were stored at 2-8 degrees for a maximum of 48-72 hours, and if transportation was delayed further, samples were stored at -80 degrees. The SARS-CoV-2 immunoglobulin G (IG) was assessed using the LIAISON® IgG chemiluminescence assay (DiaSorin, Saluggia, Italy). The method of the test used was quantitative determination of IgG anti-S1 and IgG anti-S2. The test was performed as per manufacturer instructions. The analyzer automatically calculated SARS-CoV-2 S1/S2 IgG antibody concentrations expressed as arbitrary units (AU/mL) and graded the results as follows: ≥ 15.0 was considered positive, 12.0 ≤ x <15.0 was equivocal and <12.0 was considered negative. The equivocal samples were retested on the same specimen in duplicate with the LIAISON® SARS-CoV-2 S1/S2 IgG assay. Samples with at least two out of the three results equal to or above 15.0 AU/mL should be graded positive. Samples with at least two out of the three results less than 12.0 AU/mL should be graded negative. A second sample should be collected and tested no less than one to two weeks later when the result is repeatedly equivocal. The open access national and governorate daily SARS-CoV-2 PCR confirmed data were also presented for the same period of the study to compare with the serology results. Weights were computed for the sample in such a way that they accounted for age group, sex, and nationality. The overall weighted seroprevalence, by cycle, governorate, and wilayat levels were presented. The description was also done by age group, sex, and nationality. All the weighted seroprevalence was presented with 95% CI calculated using a design-based likelihood method in the survey package in R software (Lumley, 2004) . Mapping of the prevalence at the wilayat level was conducted using 'tmap' package of R software (Tennekes, 2018) . Multivariable binary logistic regression analysis was performed to estimate the odds ratio of positive serology as the dependent variable with various independent variables namely: age group, sex, nationality, previous symptoms, previous COVID diagnosis, being a contact, history of travel, comorbidity, and occupation. Simple linear regression analysis was used to estimate the nationwide near future (up to January 2021) projected seroprevalence. All statistical analysis was done with R software version 4.0 (R Core Team Vienna, Austria). A total of 17,457 participants participated in these surveys, distributed as 4210, 4403, 4780, and 4064 for the first, second, third, and forth cycles, respectively. Thirty percent of the sample were females, 52% were in the 31-49-year-old age groups and 66.3% were Omani. These basic characteristics are elaborated more in Table 1 . Among all positive symptomatic results (N=279), fever presented in 100 participants (35.8%), loss of smell in 105 (37.6%), and cough in 92 (33.0%), supplementary Table 3 . There is a significant increase in COVID-19 seroprevalence throughout the study cycles, starting from [5.5 (4.8-6.2)] for the first cycle and ending with [22 (19.6-24.6)] for the forth cycle, Figure 1 .1. Although there are no differences between the prevalence in the age categories in each cycle, each age groups' prevalence is notably different in each proceeding cycle, except for children (5-14-years-old), Figure 1 .2 (A). There is no difference in the seroprevalence between the two sexes throughout the cycles, Figure 1.2 (B) . Nevertheless, there is a transition of seroprevalence from being more in non-Omanis in cycle one, [9.1 (7.6-10.9)] compared to Omanis [3.2 (2.6-3.9)] to being more in )] compared to non-Omanis The projected near future nationwide trend of seroprevalence is shown in Supplementary Figure 1 , showing that the seroprevalence in January 2021 is expected to be around 30 (21-38). The low estimated seroprevalence among residents of Oman in the first two cycles is comparable to other population-based studies that have been conducted around the same period or before it (Bellizzi et al, 2021; Pollán et al., 2020; Alsuwaidi et al., 2021) Over the 19 study weeks, we observed an increase in seroprevalence from about 5% to about 22% which is to be expected considering time to seroconversion after symptoms and that the peak of the first wave of the epidemic was reached the week before the start of the first cycle, and the fourth cycle was conducted after the end of the second peak (see Figures 1 and 2) . The increase in seroprevalence was similar to findings from other studies (Stringhini et al., 2020; Bellizzi et al., 2021; Murhekar et al., 2021; Hallal et al., 2020) . 15 Our study showed the comparative low risk of health care workers being infected to other categories in the community despite the increased risk of exposure at the workplace which indicates the increased risk awareness and implementation of infection prevention and control measures. However, another study we simultaneously conducted showed that the prevalence of COVID-19 infection in health care workers is a reflection of the seroprevalence in the community and that the people working in supporting services were more at risk for getting the infection than those working in high-risk areas in the hospitals such as COVID-19 wards and intensive care units (Al-Maani et al., 2021) . The seroprevalence of SARS-CoV-2 in the general population also varied across WHO regions, with a higher prevalence in the South-East Asia region (e.g., India, range: 10.8-40.8%), contrasting with a relatively lower seroprevalence in the Western Pacific region (e.g., China, range: 0.8-3.3%) (Chen et al., 2021) . Similar to other serosurveys, we found no differences among genders in SARS-CoV-2 seroprevalence (Stringhini et al., 2020; Chen et al., 2021; Rostami et al., 2021; Pollán et al., 2020; Alsuwaidi et al., 2021) . In addition, we found significant differences between age groups, mainly in the 15-30 age group compared to children 5-14; this is similar to findings from other studies that showed that children and adolescents (0-19 years) and older people (60 years) had lower seroprevalence than the other age groups (Stringhini et al., 2020; Chen et al., 2021; Pollán et al., 2020; Alsuwaidi et al., 2021; Hallal et al., 2020) . In our case, this may be a 16 reflection of school, daycare, nursery, and play area closures during the period prior and at the survey time as those areas are the main exposure places for children. We observed marked regional differences between the different governorates in Oman that generally match the surveillance data ( Figure 2) ; this could partly be due to the different epidemic introduction times to the governorates as it started from the capital governorate (Muscat) and then spread to the adjacent governorates, this has also been shown from a study from Washington, USA (Tordoff et al., 2021) . There was also earlier spread in the governorates on the borders of other countries. Regional variations in SARS-CoV-2 seroprevalence have also been reported in many other countries (Bellizzi et al., 2021; Pollán et al., 2020; Alsuwaidi et al., 2021; Poustchi et al., 2021; Núñez-Zapata et al., 2021) . The seropositivity rate was higher in migrants during the first two cycles with a subsequent increase in Omanis in the last two cycles of the study. In addition, there is a higher risk of infection in laborers compared to office workers, as supported by the logistic regression model. This is similar to other studies done in three Gulf Cooperation Council Countries (Alali et al., 2021; Alsuwaidi et al., 2021; Jeremijenko et al., 2021) . This could be explained by early in the pandemic there were many outbreaks in labor camps and dormitories that were densely populated with congregate living and lack of adherence to social distancing (Al Balushi et al., 2020; Al Fahdi et al., 2021) , and the Ministry of Health with other stakeholders implemented rigorous structured occupational health measures in workplaces and dormitories with close 17 monitoring to reduce the risk of COVID-19 transmission among this group. Later on, most of the cases were in Omanis because of family and social gatherings (Al-Mahruqi et al., 2021) . Consistently with other studies, fever, loss of smell and taste, and cough were among the symptoms with the strongest association with seropositivity (Chen et al., 2021; Alsuwaidi et al., 2021; Makaronidis et al., 2020) . In addition, our multivariable logistic regression model results confirm that close contact with people with COVID-19 almost doubles the likelihood of viral transmission; this is similar to other serosurveys (Chen et al., 2021; Pollán et al., 2020; Alsuwaidi et al., 2021; ) and highlights the importance of public health measures, including contact tracing, quarantine, and self-isolation. To our knowledge, this is the first four-cycle and the largest general population-based study of SARS-CoV2 prevalence in the WHO Eastern Mediterranean region. A key strength of our study is the random selection of households from the national telecommunication register, which allowed us to contact a representative sample of the Omani population, with a detailed sampling framework, rigorous sampling methods (i.e., multistage, stratified sampling), and adjustments for selection bias. Also, the use of a more sensitive and specific technique to screen for antibodies was an additional strength of our study. Our study has some limitations that should be noted. First, individuals with a history of COVID-19 symptoms or contacts of positive cases might be more willing to participate in the study. However, because participants were randomly selected from the population, the potential 18 effect of this limitation on our findings is expected to be low, especially with the high media coverage that preceded each cycle which resulted in a high response rate for the study. Second, some participants may have not accurately recalled the answers for all questions in the study questionnaire, resulting in possible recall bias. Nevertheless, we think that this bias is small, as in this pandemic with its increasing fears, we assume that people are more particular in remembering any respiratory symptoms during the past few months. Third, we only included children aged 5 years and older and immunological responses and susceptibility to infection might be different in younger children. Fourth, we need to consider the potential low sensitivity for individuals who were infected long before testing for the study as antibody titers wane over the months following infection (Accorsi et al., 2021) . We found a seroprevalence of 22% in the general population, and we projected it to be only 30% by January 2021, suggesting that the number of people infected by the end of 2020 was unlikely to satisfy estimates of what it would take to achieve herd immunity (Stringhini et al., 2020; Chen et al., 2021; Rostami et al., 2021; Pollán et al., 2020; Núñez-Zapata et al., 2021) . These findings emphasize the importance of prevention strategies-physical distancing, the use of face masks, identifying and isolateing new cases and their contacts-are imperative for the control of the pandemic until community immunity can be achieved through vaccination to further protect the general population from SARS-CoV-2 community transmission. In conclusion, our study provides nationwide and regional estimates of SARS-CoV-2 dissemination in Oman, showing wide variation between the different governorates in the 19 country. The substantially higher seroprevalence estimates in migrants in the first two cycles of the study reflects the high efficiency of SARS-CoV-2 spread in congregate living and working settings and the effectiveness of occupational health measures to reduce transmission put into place in these settings . The prevalence estimates remain low and are insufficient to provide herd immunity therefore bolstering the need to achieve mass vaccination.. We declare no competing interests. How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19 Epidemiological characteristics of COVID-19 confirmed cases in Muscat Governorate, Sultanate of Oman Work related clusters of COVID-19 in Muscat Governorate in Oman: Epidemiology & future implications COVID-19 epidemic monitoring after non-pharmaceutical interventions: The use of time-varying reproduction number in a country with a large migrant population Seroprevalence of SARS-CoV-2 in migrant workers in Kuwait The role of supporting services in driving SARS-CoV-2 transmission within healthcare settings: a multicenter seroprevalence study Molecular epidemiology of COVID-19 in Oman: A molecular and surveillance study for the early transmission of COVID-19 in the country Epidemiological Characteristics of Pandemic Coronavirus Disease (COVID-19) in Oman Seroprevalence of COVID-19 infection in the Emirate of Abu Dhabi, United Arab Emirates: a population-based cross-sectional study A three-phase population based sero-epidemiological study: Assessing the trend in prevalence of SARS-CoV-2 during COVID-19 pandemic in Jordan Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis Covid-19: Herd immunity is "unethical and unachievable," say experts after report of 5% seroprevalence in Spain SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys Novel coronavirus and old lessons-preparing the health system for the pandemic Clinical features of patients infected with 2019 novel coronavirus in Wuhan Herd immunity against severe acute respiratory syndrome coronavirus 2 infection in 10 communities Analysis of complex survey samples Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and/or taste in a community-based population in London, UK: An observational cohort study A novel coronavirus emerging in China-key questions for impact assessment findings from the second nationwide household serosurvey High seroprevalence for SARS-CoV-2 infection in South America, but still not enough for heard immunity! Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study Covid-19 seroprevalence rate in healthy blood donors from a community under strict lockdown measures Thematic Maps in R Initial determination of COVID-19 seroprevalence among outpatients and healthcare workers in Minnesota using a novel SARS-CoV-2 total antibody ELISA Phylogenetic estimates of SARS-CoV-2 introductions into Washington State. medRxiv Estimates of the severity of coronavirus disease 2019: a model-based analysis World Health Organization. Coronavirus disease (COVID-19) pandemic Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China This study is a collaboration between the Directorate General for Disease Surveillance and Control, the Directorate General of Primary Health Care, and the 11 Directorate Generals for Health Services in all the 11 governorates in the country. We are very thankful to all the public health and primary health care staff, nurses, and laboratory technologists who collaborated in this study. We are also grateful to all participants in the study. The authors would like to thank Lesley Carson for her editorial assistance in finalizing the manuscript.